Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07293065 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell)

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 9 words
  2. Study title expanded, about 7 wordsv3
  3. Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Start date changed from estimate of Dec 19, 2025 to Dec 15, 2025
    • Site contacts updated at 4 of 4 sites
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of the sutdy is to evaluate the protective efficacy of Recombinant Herpes Zoster Vaccine (CHO Cell) (hereinafter referred to as "the investigational vaccine") in preventing herpes zoster at 13-36 months after complete immunization with the 0- and 2-month immunization schedule in individuals aged 40 years and older.
Trial Details
NCT Number NCT07293065
Lead Sponsor MAXVAX Biotechnology Limited Liability Company
Conditions
(from sponsor)		 Herpes Zoster
Related terms Herpes Zoster
Enrollment 12,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov